These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 30569284)
1. Interethnic scaling of fraction unbound of a drug in plasma and volume of distribution: an analysis of extrapolation from Caucasians to Chinese. Yu G; Zhou HH; Zheng QS; Li GF Eur J Clin Pharmacol; 2019 Apr; 75(4):543-551. PubMed ID: 30569284 [TBL] [Abstract][Full Text] [Related]
2. Facing the Facts of Altered Plasma Protein Binding: Do Current Models Correctly Predict Changes in Fraction Unbound in Special Populations? Al-Qassabi J; Tan SPF; Phonboon P; Galetin A; Rostami-Hodjegan A; Scotcher D J Pharm Sci; 2024 Jun; 113(6):1664-1673. PubMed ID: 38417790 [TBL] [Abstract][Full Text] [Related]
3. Quantitative Estimation of Plasma Free Drug Fraction in Patients With Varying Degrees of Hepatic Impairment: A Methodological Evaluation. Li GF; Yu G; Li Y; Zheng Y; Zheng QS; Derendorf H J Pharm Sci; 2018 Jul; 107(7):1948-1956. PubMed ID: 29518400 [TBL] [Abstract][Full Text] [Related]
4. Differences in plasma binding of drugs between Caucasians and Chinese subjects. Zhou HH; Adedoyin A; Wilkinson GR Clin Pharmacol Ther; 1990 Jul; 48(1):10-7. PubMed ID: 2369804 [TBL] [Abstract][Full Text] [Related]
5. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Lombardo F; Obach RS; Shalaeva MY; Gao F J Med Chem; 2004 Feb; 47(5):1242-50. PubMed ID: 14971904 [TBL] [Abstract][Full Text] [Related]
6. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Barter ZE; Tucker GT; Rowland-Yeo K Clin Pharmacokinet; 2013 Dec; 52(12):1085-100. PubMed ID: 23818090 [TBL] [Abstract][Full Text] [Related]
7. Direct determination of the ratio of unbound fraction in plasma to unbound fraction in microsomal system (fu p/fu mic) for refined prediction of phase I mediated metabolic hepatic clearance. Deshmukh SV; Harsch A J Pharmacol Toxicol Methods; 2011; 63(1):35-9. PubMed ID: 20433934 [TBL] [Abstract][Full Text] [Related]
8. Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults. Li GF; Zheng QS; Yu Y; Zhong W; Zhou HH; Qiu F; Wang G; Yu G; Derendorf H Clin Pharmacokinet; 2019 Jul; 58(7):927-941. PubMed ID: 30767128 [TBL] [Abstract][Full Text] [Related]
9. Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women. Chiu WY; Lin CJ; Yang WS; Tsai KS; Reginster JY Osteoporos Int; 2020 Jan; 31(1):193-201. PubMed ID: 31642977 [TBL] [Abstract][Full Text] [Related]
10. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. Lombardo F; Obach RS; Shalaeva MY; Gao F J Med Chem; 2002 Jun; 45(13):2867-76. PubMed ID: 12061889 [TBL] [Abstract][Full Text] [Related]
11. Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs. Pike A; Jones B; Markandu R; O'Neill D Drug Metab Dispos; 2021 Sep; 49(9):736-742. PubMed ID: 34135088 [TBL] [Abstract][Full Text] [Related]
12. The Predictive Value of Glomerular Filtration Rate-Based Scaling of Pediatric Clearance and Doses for Drugs Eliminated by Glomerular Filtration with Varying Protein-Binding Properties. Cristea S; Krekels EHJ; Allegaert K; Knibbe CAJ Clin Pharmacokinet; 2020 Oct; 59(10):1291-1301. PubMed ID: 32314184 [TBL] [Abstract][Full Text] [Related]
13. A comparison of drug protein binding and alpha 1-acid glycoprotein concentration in Chinese and Caucasians. Feely J; Grimm T Br J Clin Pharmacol; 1991 May; 31(5):551-2. PubMed ID: 1888624 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects. Lu S; Nand RA; Yang JS; Chen G; Gross AS Eur J Clin Pharmacol; 2018 Mar; 74(3):285-296. PubMed ID: 29181698 [TBL] [Abstract][Full Text] [Related]
15. Predicting Volume of Distribution in Humans: Performance of In Silico Methods for a Large Set of Structurally Diverse Clinical Compounds. Murad N; Pasikanti KK; Madej BD; Minnich A; McComas JM; Crouch S; Polli JW; Weber AD Drug Metab Dispos; 2021 Feb; 49(2):169-178. PubMed ID: 33239335 [TBL] [Abstract][Full Text] [Related]
16. An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation. Bowman CM; Benet LZ Eur J Pharm Sci; 2018 Oct; 123():502-514. PubMed ID: 30098391 [TBL] [Abstract][Full Text] [Related]
18. Effect of Plasma Protein Binding on the Pharmacokinetics of Erdafitinib: Results of an Integrated Cross-Study Analysis. Li LY; Guo Y; Gonzalez M; Ouellet D J Clin Pharmacol; 2020 Mar; 60(3):391-399. PubMed ID: 31602692 [TBL] [Abstract][Full Text] [Related]
19. Predicting Drug Binding to Human Serum Albumin and Alpha One Acid Glycoprotein in Diseased and Age Patient Populations. McNamara PJ; Meiman D J Pharm Sci; 2019 Aug; 108(8):2737-2747. PubMed ID: 30905706 [TBL] [Abstract][Full Text] [Related]
20. Toward a new paradigm for the efficient in vitro-in vivo extrapolation of metabolic clearance in humans from hepatocyte data. Poulin P; Haddad S J Pharm Sci; 2013 Sep; 102(9):3239-51. PubMed ID: 23494893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]